FindTrial
Sign In

Optimized Response Assessment of Gastrointestinal Stromal Tumors Using Dual-Energy CT: A Prospective Multicenter-Multinational Trail in Patients Undergoing Targeted Therapy with a tyrosine-kinase-inhibitor

Optimized Response Assessment of Gastrointestinal Stromal Tumors Using Dual-Energy CT: A Prospective Multicenter-Multinational Trail in Patients Undergoing Targeted Therapy with a tyrosine-kinase-inhibitor

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
DRKS
Registry ID
DRKS00008173
Enrollment
130
Registered
2015-07-29
Start date
2014-03-03
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C16 C17 C18

Interventions

Group 1: Patients with Gastrointestinal Stromal Tumors undergoing tyrosine kinase inhibitor treatment will be assessed regarding progression-free survival and overall survival within 2 years using the

Sponsors

Universitätsklinikum Mannheim
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: All patients histological proven Gastrointestinal Stromal Tumors and undergoing systemic target treatment will be included.

Exclusion criteria

Exclusion criteria: Patients younger than 18 years or with contraindication to a contrast-enhanced CT scan.

Design outcomes

Primary

MeasureTime frame
Progression-free survival within 2 years.—

Secondary

MeasureTime frame
Overall survival within 2 years.—

Countries

Germany, Japan, United Kingdom

Contacts

Public ContactSilke Bittorf

Universitätsklinikum Mannheim

silke.bittorf@umm.de0621 383 2067

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026